Literature DB >> 16509573

Pyrazolo[3,4-d]pyrimidines as potent antiproliferative and proapoptotic agents toward A431 and 8701-BC cells in culture via inhibition of c-Src phosphorylation.

Fabio Carraro1, Antonella Naldini, Annalisa Pucci, Giada A Locatelli, Giovanni Maga, Silvia Schenone, Olga Bruno, Angelo Ranise, Francesco Bondavalli, Chiara Brullo, Paola Fossa, Giulia Menozzi, Luisa Mosti, Michele Modugno, Cristina Tintori, Fabrizio Manetti, Maurizio Botta.   

Abstract

We report here the synthesis of new pyrazolo[3,4-d]pyrimidine derivatives along with their biological properties as inhibitors of isolated Src and cell line proliferation (A431 and 8701-BC cells). Such compounds block the growth of cancer cells by interfering with the phosphorylation of Src, and they act as proapoptotic agents through the inhibition of the anti apoptotic gene BCL2. Several of them were found to be more active than the reference compound (1-(tert-butyl)-3-(4-chlorophenyl)-4-aminopyrazolo[3,4-d]pyrimidine, PP2) in inhibiting cell proliferation and in inducing apoptosis, and as active as PP2 in the inhibition of the phosphorylation of isolated Src. Moreover, molecular modeling simulations have been performed to hypothesize the way, at the molecular level, by which the inhibitors were able to act as antiproliferative agents.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16509573     DOI: 10.1021/jm050603r

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

1.  New pyrazolo-[3,4-d]-pyrimidine derivative Src kinase inhibitors lead to cell cycle arrest and tumor growth reduction of human medulloblastoma cells.

Authors:  Alessandra Rossi; Silvia Schenone; Adriano Angelucci; Martina Cozzi; Valentina Caracciolo; Francesca Pentimalli; Andrew Puca; Biagio Pucci; Raffaele La Montagna; Mauro Bologna; Maurizio Botta; Antonio Giordano
Journal:  FASEB J       Date:  2010-03-30       Impact factor: 5.191

2.  Pyrazolo[3,4-d]pyrimidine Prodrugs: Strategic Optimization of the Aqueous Solubility of Dual Src/Abl Inhibitors.

Authors:  Giulia Vignaroli; Claudio Zamperini; Elena Dreassi; Marco Radi; Adriano Angelucci; Patrizia Sanità; Emmanuele Crespan; Miroslava Kissova; Giovanni Maga; Silvia Schenone; Francesca Musumeci; Maurizio Botta
Journal:  ACS Med Chem Lett       Date:  2013-05-20       Impact factor: 4.345

3.  Pyrazolo[3,4-d]pyrimidines as inhibitor of anti-coagulation and inflammation activities of phospholipase A 2 : insight from molecular docking studies.

Authors:  Umesh Yadava; Maheshwer Singh; Mihir Roychoudhury
Journal:  J Biol Phys       Date:  2013-02-23       Impact factor: 1.365

4.  Molecular characterization of c-Abl/c-Src kinase inhibitors targeted against murine tumour progenitor cells that express stem cell markers.

Authors:  Thomas Kruewel; Silvia Schenone; Marco Radi; Giovanni Maga; Astrid Rohrbeck; Maurizio Botta; Juergen Borlak
Journal:  PLoS One       Date:  2010-11-30       Impact factor: 3.240

5.  Synthesis and antimicrobial activity of some new pyrazoles, fused pyrazolo[3,4-d]-pyrimidine and 1,2-dihydroimidazo-[2,1-c][1,2,4]triazin-6-one derivatives.

Authors:  Sobhi Mohamed Gomha; Huwaida M E Hassaneen
Journal:  Molecules       Date:  2011-08-04       Impact factor: 4.411

6.  Novel pyrazolo[3,4-d]pyrimidine derivatives as potential antitumor agents: exploratory synthesis, preliminary structure-activity relationships, and in vitro biological evaluation.

Authors:  Hai-Yun He; Jin-Ni Zhao; Ruo Jia; Ying-Lan Zhao; Sheng-Yong Yang; Luo-Ting Yu; Li Yang
Journal:  Molecules       Date:  2011-12-20       Impact factor: 4.411

7.  1-(2-Chloro-eth-yl)-1H-pyrazolo-[3,4-d]pyrimidin-4(5H)-one.

Authors:  Mohammed Iqbal A Khazi; Nikhath Fathima; Ningaraddi S Belavagi; Noor Shahina Begum; I M Khazi
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2012-06-13

8.  SRC family kinase (SFK) inhibition reduces rhabdomyosarcoma cell growth in vitro and in vivo and triggers p38 MAP kinase-mediated differentiation.

Authors:  Nadia Casini; Iris Maria Forte; Gianmarco Mastrogiovanni; Francesca Pentimalli; Adriano Angelucci; Claudio Festuccia; Valentina Tomei; Elisa Ceccherini; Domenico Di Marzo; Silvia Schenone; Maurizio Botta; Antonio Giordano; Paola Indovina
Journal:  Oncotarget       Date:  2015-05-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.